This editorial refers to 'Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry' † , by F. Gustafsson et al., on page 3454.
The treatment of patients with advanced heart failure (HF) with durable mechanically circulatory support (MCS) devices, such as left ventricular assist devices (LVADs), has improved patient survival and quality of life in comparison with treatments based on intermittent inotrope infusion programmes. Originally considered only as a lifesaving therapy for patients ineligible for heart transplantation, LVADs are now indicated for bridge transplant, myocardial recovery, or destination therapy. The proportion of LVADs implanted for destination therapy is rapidly growing. The spectacular increment in LVAD implantations observed in just one decade is mostly due to improvements in MCS technologies producing better devices able to achieve longer survival with a reasonable number of associated complications. 1, 2 In the present issue of the European Heart Journal, Gustafsson and co-workers analyse outcomes of patients included in the ELEVATE registry, 3 which recorded patients with advanced HF that were implanted with the full magnetically levitated continuous flow HeartMate 3 (HM3) after the approval of this LVAD in Kazakhstan (January 2015) and Europe (Conformité Européenne mark, October 2015). This report is of great value as it allows a better understanding of the potential benefits of this treatment strategy in real-life conditions. Recently, the clinical trial MOMENTUM-3 showed that implantation of HM3 was associated with better outcomes at 6 and 24 months than implantation of HeartMate-II, an axial flow pump, primarily because of the lower rate of re-operation to replace or remove a malfunctioning device. 4, 5 Indeed, results obtained in clinical trials are strong, as they come after randomization, explore explanatory hypothesis in highly selected populations in a strictly determined setting, control many known confounding factors, and record all scheduled data with few missing data; accordingly, their internal validity is high, with few biases and strong consistency of findings. 6 Nonetheless, those benefits are seen in selected patients who may be different in many aspects from the real-life patients seen in daily clinical practice. 7, 8 At this point, registries have the potential to complement and reinforce the clinical trial conclusions, thus allowing them to be generalized and amplified to a wider segment of patients. The analysis of the ELEVATE registry reports a good survival after 6 months of HM3 implantation: 82% for the entire cohort of 540 patients, and 92% for the 463 patients with detailed follow-up data for whom HM3 was the LVAD primary implant. Remarkably, in this latter subgroup of patients, pump thrombosis and need for pump replacement were absent, confirming previous studies with HM3. These results should be considered a clear technical advance provided by HM3 in this field. Furthermore, in the ELEVATE registry, the need for unplanned rehospitalizations was 32% and, in about the one-third of those patients who could be longitudinally assessed, they exhibited an improvement of functional capacity (measured by the six minute walk test) and quality of life (measured by the EuroQoL-5 Dimension-5 Levels). Therefore, centres participating in the ELEVATE registry have to be congratulated for achieving these impressive results, as do the authors of this report for sharing this valuable piece of experience.
The ELEVATE registry design has many strengths that merit comment. The number of patients with HM3 LVAD included (n = 540) is much larger than in previous studies with HM3 (CE Mark 1 year n = 50; MOMENTUM-3 trial n = 152 and n = 190 according to the published follow-up results at 6 months and 2 years, respectively). In the ELEVATE participating centres, all patients treated with HM3
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. were included consecutively. On the other hand, the number of patients implanted per centre (whether low or high) did not influence the results. This is another remarkable strength of the present report. Finally, in the ELEVATE registry, in comparison with other studies with HM3, there were a greater number of patients who previously received short-term MCS, which means that patients of the ELEVATE registry were sicker and at higher risk of death and complications after LVAD implantation. Indeed, in the MOMENTUM-3 trial, only an intraaortic balloon pump (IABP) was allowed, while in the ELEVATE registry 12% of patients had short-term MCS [8% extracorporeal capillary membrane oxygenation (ECMO), 2% IABP, 2% temporary extracorporeal LVAD or biventricular assist device (BiVAD), and 2% temporary percutaneous LVAD]. This illustrates, again, the differences between the real-life registries and the ideal world where randomized clinical trials are conducted.
Certainly, the study of Gustafsson et al. has limitations, some raised by the authors. The most important one is the lack of information about complications in the 58 patients (11% of the whole cohort) that were included after death for whom the review of details of medical history was not waived by Ethical Committees. Quite expectedly, complications in this subset of patients could have been higher than in longer term survivors. In addition to that, some limitations have to be considered for better contextualizing the reported results. First, in order to consider the ELEVATE results as representative of real life, the authors should have included all centres using HM3 in the countries involved in the registry. It is not clear whether this was the case because, while some countries such as Germany participated with 12 hospitals, others such as Italy, the UK, and the Netherlands participated with only very few centres. It is therefore possible that only the highly interested/experienced centres participated in the registry and reported cases. However, the fact that each participating centre reported all consecutive implanted HM3 LVADs could have mitigated this bias. Secondly, reasons for selection of the HM3 LVAD, in competition with other continuous centrifugal flow LVADs, including the HeartWare ventricular assist device (HVAD), are not provided, leaving the possibility that patients finally receiving the HM3 LVAD constituted a selected group with special characteristics. In real life, the assignment of patients to a particular device is based on many considerations, and even in this uncontrolled environment, some inclusion criteria for patient allocation to a specific LVAD exist, and may vary from one centre to another. This is an additional potential source of bias that could influence potential mismatches with outcomes obtained in other countries or by other teams.
Whether the ELEVATE registry analysis, on top of the MOMENTUM-3 trial, provides arguments to recommend HM3 over other LVADs in general or in a subset of patients with a failing heart is not answered by this study. To our knowledge, a head to head comparison between third-generation centrifugal pumps has not been done so far. Currently, there are two small intrapericardial continuous centrifugal flow LVADs: HVAD and HM3. While HVAD incorporates a bearingless design with magnetic and hydrodynamic levitation of the internal impeller, HM3 is designed to reduce shear stress on blood elements further and to avoid pump thrombosis. HM3 has a fully magnetically levitated rotor, engineered with wide blood flow passages and no mechanical bearings, is frictionless, and is programmed to facilitate rapid changes in rotor speed to create an intrinsic artificial pulse. This fixed pulse, which is asynchronous with the native heartbeat, reduces stasis in the pump and allows for more complete washing of pump surfaces. This potential to reduce haemocompatibility-related events is one of the main improvements of HM3 over the other LVADs. Hypothetically, HM3 would allow the reduction of the intensity of anticoagulation by taking advantage of its lower incidence of pump thrombosis. Although of small size (n = 15), the results of a recent study are congruent with this hypothesis, 9 and hopefully it should be proved by a large clinical trial. Ultimately, clinical trials based on head to head comparison will be a way to help cardiologists and cardiac surgeons make the best decision for their patients and to best assess the balance between efficacy and safety. In this sense, complications reported in the ELEVATE registry related to HM3 implantation were not of insignificant frequency, as 35% of patients developed infections (12% driveline, 9% sepsis), 25% bleeding (10% requiring surgery), 15% right heart failure (7% requiring right ventricular assist device placement), and 5% stroke. Although most of them were not superior to previous experiences with HM3 in more controlled environments (CE Mark study 10, 11 and MOMENTUM-3 trial 4, 5 ), two main issues have to be borne in mind. First, these reported figures for complications in the ELEVATE registry did not include patients from the anonymized cohort and patients implanted as a replacement for another LVAD, for whom a higher mortality was reported. Secondly, there is no indication that safety events were monitored in situ in ELEVATE as they were in trials such as MOMENTUM-3. Even though it is foreseeable that the most frequent adverse events, infections and bleeding, could be diminished in the near future as peri-procedural care improves and further improvements of LVAD are implemented, marked reduction of complications is clearly the next challenge for care givers and LVAD manufacturers. A quick glance at how these adverse events are still negatively impacting post-operative quality of life one decade after the LVAD explosion allows us to better pinpoint the most urgent challenges to face in the next coming years (Take home figure) . 3, 4, [10] [11] [12] [13] Conflicts of interest: M.G.C.-L. has received personal fees (travel grants and/or lecture) from Abbott and HeartWare. All other authors have no conflicts to declare.
